Doncaster Pharma Limited, Hiprex 1g tablets medicines defect
Class 4 medicines defect notification: The MHRA has published a class 4 medicines defect notification for Hiprex 1g tablets.
Published: 22 April 2026
Doncaster Pharma Limited has informed the Medicines and Healthcare products Regulatory Agency (MHRA) of an error related to the Braille embossing on the outer packaging of certain parallel imported batches of Hiprex 1 g tablets (POM). It was identified that the embossed Braille text on the outer packaging incorrectly states the strength as 1mg. The printed text on the outer packaging, immediate packaging and Patient Information Leaflet (PIL) correctly state the strength as 1g.
Further information, advice and details of the affected batches can be found on the MHRA website.